Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abeona Therapeutics
(NQ:
ABEO
)
4.790
+0.720 (+17.69%)
Streaming Delayed Price
Updated: 10:15 AM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abeona Therapeutics
< Previous
1
2
3
4
5
Next >
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
November 27, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Recap: Abeona Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
November 13, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Recap: Abeona Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
The 7 Most Undervalued Penny Stocks to Buy in October 2023
October 06, 2023
Undervalued penny stocks offer tremendous return for investors with an appetite for risk but these shares are relatively safe as well.
Via
InvestorPlace
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
September 26, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Blockbusters to Turn $5,000 Into $50,000
September 12, 2023
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time.
Via
InvestorPlace
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
September 12, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
September 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
August 30, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 02, 2023
Via
Benzinga
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
July 28, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Joins Rare Disease Company Coalition
July 19, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 07, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 03, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
June 09, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
May 22, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 16, 2023
Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
May 11, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 10, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
March 29, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants
March 24, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
March 16, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
March 14, 2023
From
Abeona Therapeutics Inc.
Via
GlobeNewswire
Three Small-Cap Biotech Stocks to Consider Now
December 12, 2022
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023
Via
MarketBeat
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
November 21, 2022
We're checking in on the top short squeeze stocks to watch this week as traders continue to have an interest in this part of the market!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.